Literature DB >> 17323337

The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin.

Ken Shirabe1, Shinji Itoh, Tomoharu Yoshizumi, Yuji Soejima, Akinobu Taketomi, Shin-Ichi Aishima, Yoshihiko Maehara.   

Abstract

The microvascular invasion of cancer cells (mvi) is a good prognostic factor after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC). The aim of this study is to predict mvi in patients with HCC who were candidates for OLT. We studied 218 patients with HCC resections who had HCC without any extrahepatic metastases and vascular invasion detected during preoperative evaluation. We analyzed the clinico-pathological data of these patients to predict the mvi presence. The mvi prediction scoring system was made and the accuracy of this system was examined using independent clinico-pathologic factors. The size and histological grade of the tumor were significantly correlated with the mvi. The des-gamma-carboxy prothrombin (DCP) is a mvi predictor. The sensitivity of our mvi prediction system was 75% and the specificity was 85% in 32 patients who underwent living-donor liver transplantations for HCC. Our study shows that besides the tumor size and histological grade, a measurement of the serum DCP levels could be a good predictor for mvi. A tumor biopsy and a preoperative measurement of DCP could improve the selection of patients with HCC for OLT. Our scoring system for mvi provides us a precise prediction of the presence of mvi.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323337     DOI: 10.1002/jso.20655

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  63 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

2.  Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria.

Authors:  Seung Duk Lee; Bora Lee; Seong Hoon Kim; Jungnam Joo; Seok-Ki Kim; Young-Kyu Kim; Sang-Jae Park
Journal:  World J Transplant       Date:  2016-06-24

3.  Significance of Glypican-3 in Early Detection of Hepatocellular Carcinoma in Cirrhotic Patients.

Authors:  Ahmed M Tahon; Magdy Z El-Ghanam; Samy Zaky; Tarek Mostafa Emran; Ali M Bersy; Fathiya El-Raey; Elsayed A Z; Amr M El Kharsawy; Dina Johar
Journal:  J Gastrointest Cancer       Date:  2019-09

4.  Hepatocellular carcinoma biology predicts survival outcome after liver transplantation in the USA.

Authors:  Mohamed Abd El-Fattah
Journal:  Indian J Gastroenterol       Date:  2017-02-14

5.  Clinical outcome of hepatectomy for hepatocellular carcinomas≤2 cm.

Authors:  Tokihiko Sawada; Keiichi Kubota; Junji Kita; Masato Kato; Takayuki Shiraki; KyungHwa Park; Mitsugi Shimoda
Journal:  World J Surg       Date:  2011-02       Impact factor: 3.352

6.  Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection.

Authors:  Susumu Eguchi; Mitsuhisa Takatsuki; Masaaki Hidaka; Akihiko Soyama; Tetsuo Tomonaga; Izumi Muraoka; Takashi Kanematsu
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

Review 7.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization.

Authors:  Takuma Arai; Akira Kobayashi; Ayumi Ohya; Masaaki Takahashi; Takahide Yokoyama; Akira Shimizu; Hiroaki Motoyama; Norihiko Furusawa; Tsuyoshi Notake; Noriyuki Kitagawa; Hiroshi Sakai; Hiroshi Imamura; Masumi Kadoya; Shin-Ichi Miyagawa
Journal:  Int J Clin Oncol       Date:  2013-11-12       Impact factor: 3.402

Review 10.  Diagnosis of hepatocellular carcinoma.

Authors:  Asmaa I Gomaa; Shahid A Khan; Edward L S Leen; Imam Waked; Simon D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.